According to Gram Research analysis, a protein called YTHDF1 significantly worsens atherosclerosis by stabilizing another protein called BRD4, which causes blood vessel cells to transform into harmful cell types. When researchers removed YTHDF1 from mice prone to heart disease, plaque buildup in their arteries decreased by more than 50 percent and fatty deposits dropped by more than 60 percent, suggesting that blocking this protein could become a new strategy for treating atherosclerosis.
Scientists found that a protein called YTHDF1 plays a major role in making heart disease worse. This protein works by stabilizing another protein called BRD4, which causes blood vessel cells to change into a different type of cell. When researchers removed YTHDF1 from mice prone to heart disease, the mice developed much smaller plaques in their arteries and had less damage to their blood vessels. This discovery suggests that blocking YTHDF1 could be a new way to treat atherosclerosis, the buildup of plaque in arteries that causes heart attacks and strokes.
Key Statistics
A 2026 research study found that YTHDF1 protein levels were significantly elevated in atherosclerotic plaques from 104 human patients compared to healthy tissue, establishing the protein’s role in heart disease progression.
In mice lacking the YTHDF1 gene, atherosclerotic plaque area decreased by more than 50 percent and lipid deposition dropped by more than 60 percent compared to control mice fed a high-fat diet, demonstrating the protein’s critical role in disease development.
Laboratory experiments showed that human blood vessel cells overexpressing YTHDF1 displayed 1.53 times higher levels of BRD4 protein and significantly increased cell migration compared to control cells, indicating enhanced atherosclerosis-promoting activity.
When BRD4 was removed from cells with elevated YTHDF1, the harmful cell transformation and increased migration were suppressed, proving that BRD4 is the essential protein through which YTHDF1 causes atherosclerosis damage.
The Quick Take
- What they studied: How a protein called YTHDF1 contributes to atherosclerosis, the disease where plaque builds up in arteries and hardens them, making it harder for blood to flow.
- Who participated: The research included 110 human tissue samples from patients with atherosclerosis, 3 mice with genetic modifications, and laboratory-grown human blood vessel cells. Scientists also studied mice bred to develop heart disease naturally.
- Key finding: When YTHDF1 was removed from mice prone to atherosclerosis, plaque buildup in their arteries decreased by more than 50 percent, and fatty deposits dropped significantly. In lab tests, cells with extra YTHDF1 showed increased movement and changes that make atherosclerosis worse.
- What it means for you: This research identifies a new target for treating heart disease, but it is still in early stages. Doctors cannot yet use this information to treat patients, but it opens the door for developing new medicines that could slow or prevent atherosclerosis progression.
The Research Details
This study combined multiple research approaches to understand how YTHDF1 causes atherosclerosis. First, scientists analyzed tissue samples from patients with atherosclerosis and compared them to healthy tissue, looking for differences in YTHDF1 levels. They also studied genetic data from mice to see how YTHDF1 behaves in living animals.
Next, researchers created special mice that lacked the YTHDF1 gene and fed them a high-fat diet to trigger atherosclerosis. They measured how much plaque formed in these mice compared to normal mice. Finally, they grew human blood vessel cells in the laboratory and added or removed YTHDF1 to see what happened to the cells’ behavior and their ability to move around.
To understand the exact mechanism, scientists used specialized techniques to identify where YTHDF1 attaches to messenger RNA molecules and how it changes their stability. This combination of human tissue analysis, animal studies, and laboratory experiments provided strong evidence for their findings.
Understanding the exact steps that cause atherosclerosis is crucial for developing new treatments. Most current heart disease medications work by lowering cholesterol or reducing inflammation, but they do not address all the ways atherosclerosis develops. By identifying the YTHDF1 pathway, researchers found a completely new mechanism that could be targeted with future drugs. This approach could help patients who do not respond well to existing treatments.
This study has several strengths that make its findings reliable. The researchers used both human tissue samples and animal models, which strengthens their conclusions. They employed multiple laboratory techniques to confirm their findings, and the results were consistent across different experiments. The statistical analysis showed clear differences between groups, with p-values below 0.01 for most key findings, meaning the results are unlikely to be due to chance. However, the study was conducted in laboratory and animal settings, so results may not directly translate to humans yet.
What the Results Show
YTHDF1 protein was found at much higher levels in atherosclerotic plaques from patients compared to healthy tissue. When researchers removed the YTHDF1 gene from mice prone to atherosclerosis, the mice developed significantly smaller plaques. Specifically, plaque area decreased by more than 50 percent, and fatty deposits inside the plaques dropped by more than 60 percent.
In laboratory experiments with human blood vessel cells, adding extra YTHDF1 caused cells to change into a different type of cell that promotes atherosclerosis. These cells also moved around more easily, which is a sign they were becoming more dangerous. The cells with extra YTHDF1 showed 1.53 times more BRD4 protein compared to normal cells.
When scientists removed BRD4 from cells with high YTHDF1, the harmful effects disappeared. This proved that BRD4 is the key protein through which YTHDF1 causes damage. The research showed that YTHDF1 works by attaching to BRD4 messenger RNA and keeping it stable, allowing more BRD4 protein to be made.
The study revealed that YTHDF1 works through a specific chemical modification of RNA called m6A methylation. This modification acts like a label that tells YTHDF1 where to attach to messenger RNA. When this label was removed from BRD4 messenger RNA, YTHDF1 could no longer stabilize it, and BRD4 levels dropped. This finding shows that the entire pathway depends on this specific chemical marking system. Additionally, mice lacking YTHDF1 showed less transformation of blood vessel cells into other cell types, suggesting the protein is essential for this harmful change.
Previous research established that BRD4 is important in atherosclerosis, but scientists did not know how BRD4 levels were controlled. This study fills that gap by showing that YTHDF1 regulates BRD4 through RNA stability. The m6A methylation system has been studied in cancer and inflammation, but its role in atherosclerosis was not well understood. This research expands our knowledge of how this chemical marking system affects heart disease. The findings also connect three previously separate areas of research: RNA modification, epigenetic regulation, and atherosclerosis progression.
This study was conducted primarily in mice and laboratory cells, not in humans, so results may not directly apply to patients yet. The mouse model used was genetically modified to develop atherosclerosis quickly, which may not perfectly represent how the disease develops in humans. The study did not test any potential drugs or treatments based on these findings, so it is unclear whether blocking YTHDF1 would be safe or effective in people. Additionally, the research focused on one specific pathway, but atherosclerosis is a complex disease with many contributing factors. Long-term effects of removing YTHDF1 were not studied, so potential side effects remain unknown.
The Bottom Line
Based on this research, there are currently no direct recommendations for patients. The findings are too early-stage for clinical application. However, this research suggests that future medications targeting the YTHDF1-BRD4 pathway could help prevent or slow atherosclerosis progression. Patients should continue following established heart disease prevention strategies: maintaining a healthy diet low in saturated fat, exercising regularly, not smoking, and taking prescribed medications like statins if recommended by their doctor. This research may eventually lead to new treatment options, but that is likely years away.
This research is most relevant to people at high risk for atherosclerosis, including those with high cholesterol, high blood pressure, diabetes, or a family history of heart disease. Cardiologists and researchers studying heart disease should pay close attention to these findings. People currently taking heart disease medications should not change their treatment based on this study. This research is also important for pharmaceutical companies developing new heart disease drugs, as it identifies a new target for drug development.
If this research leads to drug development, it typically takes 5 to 10 years to move from laboratory findings to human testing, and another 5 to 10 years for regulatory approval. Realistic expectations are that any new treatment based on this pathway would not be available to patients for at least 10 to 15 years. In the near term, this research may lead to more studies in animal models and laboratory experiments to confirm these findings and test potential drugs.
Frequently Asked Questions
What is YTHDF1 and why does it matter for heart disease?
YTHDF1 is a protein that controls how stable other messenger RNA molecules are. Research shows it worsens atherosclerosis by keeping BRD4 messenger RNA stable, leading to more BRD4 protein production. This increased BRD4 causes blood vessel cells to change into harmful cell types that promote plaque buildup in arteries.
Can I get tested for YTHDF1 levels to check my heart disease risk?
Currently, YTHDF1 testing is not available for patients. This research is still in early laboratory and animal stages. Your doctor can assess heart disease risk using established methods like cholesterol levels, blood pressure, and family history. Future tests may become available once this research advances to human studies.
When will treatments targeting YTHDF1 be available?
Treatments based on this research are likely 10 to 15 years away. Scientists must first confirm these findings in additional studies, then develop and test potential drugs in animals and humans. Even promising laboratory discoveries typically require a decade or more before becoming available to patients.
Should I change my heart disease treatment based on this study?
No, continue taking medications prescribed by your doctor. This research has not been tested in humans yet and does not change current treatment recommendations. Continue following proven strategies: maintain a healthy diet, exercise regularly, manage cholesterol and blood pressure, and take prescribed medications as directed.
How does YTHDF1 actually cause atherosclerosis to get worse?
YTHDF1 recognizes a chemical marking system on BRD4 messenger RNA and keeps it stable longer. This allows more BRD4 protein to be made. Excess BRD4 then causes blood vessel cells to transform into different cell types that promote plaque formation and atherosclerosis progression in arteries.
Want to Apply This Research?
- Users at risk for atherosclerosis should track their cardiovascular health markers weekly: blood pressure readings, dietary fat intake in grams, and exercise minutes. Log these metrics alongside any new medications or supplements to identify patterns that affect heart health.
- Implement a weekly heart-healthy meal plan that reduces saturated fat intake to under 10 percent of daily calories. Use the app to log meals, track saturated fat content, and receive alerts when approaching daily limits. This directly supports atherosclerosis prevention while research develops new treatments.
- Establish a monthly cardiovascular health review within the app. Compare blood pressure trends, cholesterol levels from lab work, exercise consistency, and diet quality. Set reminders for annual doctor visits to check cholesterol and blood pressure, and share tracked data with healthcare providers to inform treatment decisions.
This research is preliminary and has not been tested in humans. The findings are based on laboratory experiments and animal studies, which may not directly translate to human disease. This article is for educational purposes only and should not be used to diagnose, treat, or prevent any disease. Anyone concerned about atherosclerosis or heart disease should consult with a qualified healthcare provider. Do not change any medications or treatments based on this research without discussing it with your doctor. Future clinical trials will be needed to determine whether targeting YTHDF1 is safe and effective in patients.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.